论文部分内容阅读
异丁基哌嗪力复霉素(代号R76-1)由四川抗菌素工业研究所于1976年初步研制成功。1977年后又与四川长征制药厂、无锡第一制药厂协作,进行工艺研究并生产出部分样品供科研用。据一系列的临床前药理试验结果证明,异丁基哌嗪力复霉素对结核杆菌具有与利福平相似或甚至稍强的抗菌作用,两药间有交叉耐药性,对动物实验性结核病也有良好疗效,而且还具有口服毒性低吸收良好等优点。为验证其临床疗效如何,我们19个临床单位在统一选例标准和临床观察项目后,自1980年4月起陆续地开展了异丁基哌嗪力复霉素对肺结核病人的临床治疗观察,现将资料齐全、疗程满六个月的332例资料分析于后。
Isobutylpiperazine rifamycin (code R76-1) by the Sichuan Institute of antibiotics in 1976, initially successfully developed. After 1977, he cooperated with Sichuan Changzheng Pharmaceutical Factory and Wuxi No.1 Pharmaceutical Factory to conduct process research and produce some samples for scientific research. According to a series of preclinical pharmacological test results show that isobutylpiperazine rifamycins against Mycobacterium tuberculosis with rifampicin similar or even slightly stronger antibacterial effect, there is cross-resistance between the two drugs on animal experimental Tuberculosis also has good efficacy, but also has the advantages of low oral toxicity and good absorption. To verify the clinical efficacy of how our 19 clinical units in the uniform selection criteria and clinical observation of the project, since April 1980 onwards carried out isobutylpiperazine fructancomycin clinical observation of tuberculosis patients, Now the information is complete, course of treatment of six months after 332 cases of data analysis.